This first installment observes how the adjuvant treatment landscape has evolved for patients with HR+/HER2- early breast cancer, including discussion on the monarchE study.
Chair, Cancer Committee, Advocate Lutheran General Hospital (ALGH), Medical Director, ALGH Survivorship Program, Director, Oncology Specialists Research Institute